MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering

MetaVia Announces the Pricing of $8.1 Million

Underwritten Public Offering

CAMBRIDGE, Mass., Jan. 15, 2026 - MetaVia

Inc. (Nasdaq: MTVA) (MetaVia or the Company), a clinical-stage biotechnology company focused on transforming cardiometabolic

diseases, today announced the pricing of its underwritten public offering of shares of common stock (or common stock equivalents) and

Series C Warrants and Series D Warrants for gross proceeds of approximately $8.1 million, prior to deducting underwriting discounts

and commissions and offering expenses and excluding any potential future proceeds from the exercise of warrants.

The underwritten public offering is comprised

of an aggregate of 2,613,544 shares of common stock (or common stock equivalents), 3,920,316 Series C Warrants and 3,920,316 Series D

Warrants priced at a combined public offering price of $3.10 per share of common stock and accompanying Series C Warrants and Series D

Warrants. The Series C Warrants are immediately exercisable, have an exercise price of $3.10, and expire on the five year anniversary

of the initial issuance date. The Series D Warrants are immediately exercisable, have an exercise price of $3.10, and expire

on the two year anniversary of the initial issuance date. The Series D Warrants are callable at the Company's option following

the release of a positive data readout for its Phase 1b Part III clinical trial for DA-1726 via a widely disseminated press release,

subject to satisfaction of certain conditions. The Series C Warrants and Series D Warrants issued in this offering are fixed

priced and do not contain any variable pricing features or alternative exercise provisions.

Ladenburg Thalmann & Co. Inc. is acting

as sole book-running manager in connection with the underwritten public offering.

If fully exercised for cash, the Pre-Funded Warrants,

the Series C Common Warrants and the Series D Common Warrant could yield up to approximately an additional $24.0 million in

future gross proceeds. MetaVia intends to use the net proceeds from the underwritten public offering for working capital and general corporate

purposes, including to continue the clinical development of DA-1726 for the treatment of obesity.

In addition, MetaVia granted the underwriters

a 45-day option to purchase up to an additional 392,030 shares of common stock, 588,045 Series C Warrants and 588,045 Series D

Warrants, at the public offering price of $3.10 per share, less underwriting discounts and commissions.

This underwritten public offering is expected

to close on or about January 16, 2026, subject to the satisfaction of customary closing conditions.

The securities issued as part of the underwritten

public offering were offered pursuant to a registration statement on Form S-1 (File No. 333-292581), which was initially filed

with the U.S. Securities and Exchange Commission ("SEC") on January 5, 2026, as amended on January 12, 2026, and

declared effective on January 15, 2026 and an additional registration statement on Form S-1 filed pursuant to Rule 462(b),

which was filed on January 15, 2026 and became effective upon filing.

This press release does not constitute an offer

to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer,

solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The underwritten

public offering is being made solely by means of a prospectus. A final prospectus relating to this underwritten public offering will be

filed by MetaVia with the SEC. When available, copies of the final prospectus can be obtained at the SEC's website at www.sec.gov or from

Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com.

MetaVia Inc. is a clinical-stage biotechnology

company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and

is developing vanoglipel (DA-1241) for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin

(OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring

gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting

in superior body weight loss compared to selective GLP1R agonists. In a Phase 1 multiple ascending dose (MAD) trial in obesity, DA-1726

demonstrated best-in-class potential for weight loss, glucose control, and waist reduction. Vanoglipel (DA-1241) is a novel G-protein-coupled

receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, vanoglipel (DA-1241)

demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis,

hepatic inflammation, and liver fibrosis, while also improving glucose control. In a Phase 2a clinical study, vanoglipel (DA-1241) demonstrated

direct hepatic action in addition to its glucose lowering effects.

For more information, please visit www.metaviatx.com.

Forward Looking Statements

Certain statements in this press release may be

considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes",

"expects", "anticipates", "may", "will", "should", "seeks", "approximately",

"potential", "intends", "projects", "plans", "estimates" or the negative of these words

or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended

to identify forward-looking statements, which include, among other statements, statements regarding the anticipated use of the net proceeds

from the underwritten public offering, the potential future gross proceeds from the underwritten public offering, and the expected closing

date of the underwritten public offering. Forward-looking statements are predictions, projections and other statements about future events

that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause

actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those

risks associated with MetaVia's ability to execute on its commercial strategy; MetaVia's expectations regarding the sufficiency of its

existing cash on hand to fund MetaVia's operations; the timeline for regulatory submissions; the ability to obtain regulatory approval

through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement

with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract

manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential

negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's

ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether

MetaVia receives results from MetaVia's clinical trials that are consistent with the results of pre-clinical and previous clinical trials;

impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating

to the license agreement; the effects of changes in applicable laws or regulations; the effects of changes to MetaVia's stock price on

the terms of the license agreement and any future fundraising; and other risks and uncertainties described in MetaVia's filings with the

Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on

Form 10-Q. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update

or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Marshall H. Woodworth

Chief Financial Officer

Rx Communications Group